'Ii study' diaporamas de présentation

Novel and Emerging Therapeutic Strategies in the Management of Non-Small Cell Lung Cancer

Novel and Emerging Therapeutic Strategies in the Management of Non-Small Cell Lung Cancer. Matthew Gubens , MD, MS Associate Professor, Thoracic Medical Oncology University of California, San Francisco San Francisco, California. Grand Rounds Program Steering Committee.

954 views • 54 slides

Update: New Treatment Modalities

A S H. 2 0 0 8. Update: New Treatment Modalities. ASH 2008 : Update on new treatment modalities. GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant disease

577 views • 40 slides

Novel treatment options for Waldenstrom Macroglobulinemia

Novel treatment options for Waldenstrom Macroglobulinemia. Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA. Ghobrial et al, Lancet Oncol 2004, Treon et al, Blood 2009. MYD88 in WM. Treon et al, NEJM 2012.

460 views • 37 slides

One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory

One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004. Hari Cheryl Sachs, MD, FAAP Medical Officer Division of Pediatric Drug Development Center for Drug Evaluation and Research

447 views • 27 slides

Cancer Center Trials at St. Barnabas Medical Center

Cancer Center Trials at St. Barnabas Medical Center. Oncology clinical research at Saint Barnabas Medical Center (SBMC) is supported by a staff of three.

316 views • 19 slides

Milano, 10/11/2006

Milano, 10/11/2006. Double Beta Decay in ILIAS-next. Andrea Giuliani. v. v. Main objective. develop specific aspects of various detector technologies (both classical and innovative) aiming at improving the sensitivity in the search for rare events. ameliorate existing experiments.

226 views • 16 slides

243 views • 14 slides

Kumar SK et al. Proc ASH 2012;Abstract 332.

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma. Kumar SK et al. Proc ASH 2012;Abstract 332. Background.

256 views • 11 slides

A Study of the VWOG

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG. Caelyx and Gemcitabine in recurrent ovarian cancer. Rationale.

94 views • 9 slides

Borthakur G et al. Proc ASCO 2011;Abstract 6506.

Phase I/II Trial of the MEK1/2 Inhibitor GSK1120212 (GSK212) in Patients with Relapsed/ Refractory Myeloid Malignancies: Evidence of Activity in Pts with RAS Mutation. Borthakur G et al. Proc ASCO 2011;Abstract 6506. Background.

218 views • 8 slides

Ades L et al. Proc ASH 2010;Abstract 508.

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone des Myelodysplasies (GFM). Ades L et al. Proc ASH 2010;Abstract 508. Background.

195 views • 7 slides